摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

10aH-1-Benzoxocin | 265-69-0

中文名称
——
中文别名
——
英文名称
10aH-1-Benzoxocin
英文别名
(2Z,4Z,6Z)-10aH-1-benzoxocine
10aH-1-Benzoxocin化学式
CAS
265-69-0
化学式
C11H10O
mdl
——
分子量
158.2
InChiKey
KZGZRHNYXCSCJG-VQXHACBYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • Drug conjugates
    申请人:Ojima Iwao
    公开号:US20050232928A1
    公开(公告)日:2005-10-20
    A compound having the formula Y-A-Z, wherein: A is a 5, 6, or 7 member ring that is monocyclic or is fused to 1 to 3 additional 4 to 8 member rings; wherein ring A and, independently, the fused additional rings are carbocyclic or heterocyclic, and saturated or unsaturated, wherein unsaturated rings are aromatic or non-aromatic; wherein Y and Z are substituents at adjacent positions on ring A; Y represents: Z represents: X and E represent O, S, or NR a or NR b ; each of a, b, c, d, e and f independently represents 0 or 1; a+c equals 0, 1, or 2; b+d equals 0, 1, or 2; a+b+c+d+e+f equals 1, 2, or 3; provided that when f is 1, then d is 1, and when d is 0, then f is 0; and when both e and b are 0, then neither R 1 nor R 1 is chloro or bromo; v represents 0 or 1, provided that when v is 0, then J is hydrogen, a metal ion, or a quaternary ammonium ion; and X is O and G is H; either G is hydrogen, a metal ion, a quaternary ammonium ion, lower alkyl, or comprised of a pharmaceutically active chemical compound or the precursor thereof; or X-G represents a carbonyl-activating group; J is lower alkyl, aryl, heteroaryl, omega-hydroxycarbonyl-(lower alkyl), omega-(lower alkoxy)carbonyl-(lower alkyl), omega-(X-G)-carbonyl-(lower alkyl) group, or comprised of a specific binding agent; and R a , R b , R 1 , R 2 , R 3 , R 4 are as defined in the specification.
    具有Y-A-Z分子式的化合物,其中:A是一个5、6或7成员环,可以是单环的,也可以与1至3个额外的4至8成员环融合;其中环A和额外融合的环独立地可以是碳环或杂环,饱和或不饱和,不饱和环可以是芳香的或非芳香的;其中Y和Z是环A上相邻位置的取代基;Y代表:Z代表:X和E代表O、S或NRa或NRb;a、b、c、d、e和f中的每一个独立地代表0或1;a+c等于0、1或2;b+d等于0、1或2;a+b+c+d+e+f等于1、2或3;条件是当f为1时,d为1,当d为0时,f为0;当e和b都为0时,R1和R1都不是;v代表0或1,条件是当v为0时,J为氢、属离子或季离子;X为O且G为H;G为氢、属离子、季离子、低碳基,或由药用活性化学化合物或其前体组成;或者X-G代表一个羰基活化基团;J为低碳基、芳基、杂环基、ω-羟基羰基-(低碳基)、ω-(低烷氧基)羰基-(低碳基)、ω-(X-G)-羰基-(低碳基)基团,或由特异结合剂组成;而Ra、Rb、R1、R2、R3、R4如规范中所定义。
  • DRUG CONJUGATES
    申请人:Ojima Iwao
    公开号:US20080139815A1
    公开(公告)日:2008-06-12
    A compound having the formula Y-A-Z, wherein: A is a 5, 6, or 7 member ring that is monocyclic or is fused to 1 to 3 additional 4 to 8 member rings; wherein ring A and, independently, the fused additional rings are carbocyclic or heterocyclic, and saturated or unsaturated, wherein unsaturated rings are aromatic or non-aromatic; wherein Y and Z are substituents at adjacent positions on ring A; Y represents: Z represents: X and E represent O, S, or NR a or NR b ; each of a, b, c, d, e and f independently represents 0 or 1; a+c equals 0, 1, or 2; b+d equals 0, 1, or 2; a+b+c+d+e+f equals 1, 2, or 3; provided that when f is 1, then d is 1, and when d is 0, then f is 0; and when both e and b are 0, then neither R 1 nor R 2 is chloro or bromo; v represents 0 or 1, provided that when v is 0, then J is hydrogen, a metal ion, or a quaternary ammonium ion, and X is O and G is H; either G is hydrogen, a metal ion, a quaternary ammonium ion, lower alkyl, or comprised of a pharmaceutically active chemical compound or the precursor thereof; or X-G represents a carbonyl-activating group; J is lower alkyl, aryl, heteroaryl, omega-hydroxycarbonyl-(lower alkyl), omega-(lower alkoxy)carbonyl-(lower alkyl), omega-(X-G)-carbonyl-(lower alkyl) group, or comprised of a specific binding agent; and R a , R b , R 1 , R 2 , R 3 , R 4 are as defined in the specification.
    化合物的化学式为Y-A-Z,其中:A是一个5、6或7个成员环,可以是单环或与1到3个其他4到8个成员环融合;其中,环A和独立的融合环均为碳环或杂环,饱和或不饱和,不饱和环为芳香或非芳香;Y和Z是环A上相邻位置的取代基;Y代表:Z代表:X和E代表O、S或NRa或NRb;a、b、c、d、e和f中的每一个都独立地表示0或1;a+c等于0、1或2;b+d等于0、1或2;a+b+c+d+e+f等于1、2或3;但当f为1时,则d为1,当d为0时,则f为0;当e和b都为0时,则R1和R2均不是;v表示0或1,但当v为0时,则J为氢、属离子或季离子,而X为O且G为H;G可以是氢、属离子、季离子、低碳基或由药物活性化合物或其前体组成;或者X-G表示一个羰基活化基团;J是低碳基、芳基、杂环基、ω-羟基羧酸-(低碳基)、ω-(低烷氧基)羧酸-(低碳基)、ω-(X-G)-羧酸-(低碳基)基团,或由特定结合剂组成;Ra、Rb、R1、R2、R3、R4如说明书所定义。
  • US7282590B2
    申请人:——
    公开号:US7282590B2
    公开(公告)日:2007-10-16
  • US7847119B2
    申请人:——
    公开号:US7847119B2
    公开(公告)日:2010-12-07
  • [EN] DRUG CONJUGATES<br/>[FR] CONJUGUES DE MEDICAMENTS
    申请人:UNIV NEW YORK STATE RES FOUND
    公开号:WO2005079398A2
    公开(公告)日:2005-09-01
    A compound having the formula Y - A - Z, wherein: A is a 5, 6, or 7 member ring that is monocyclic or is fused to 1 to 3 additional 4 to 8 member rings; wherein ring A and, independently, the fused additional rings are carbocyclic or heterocyclic, and saturated or unsaturated, wherein unsaturated rings are aromatic or non-aromatic; whereinY and Z are substituents at adjacent positions on ring A; Y represents Formula (I); Z represents Formula (II); X and E represent O, S, or NRa or NRb; each of a, b, c, d, e and f independently represents 0 or 1; a + c equals 0, 1, or 2; b + d equals 0, 1, or 2; a + b + c + d + e + f equals 1, 2, or 3; provided that when f is 1, then d is 1, and when d is 0, then f is 0; and when both e and b are 0, then neither R1 nor R2 is chloro or bromo; v represents 0 or 1, provided that when v is 0, then J is hydrogen, a metal ion, or a quaternary ammonium ion; and X is O and G is H; either G is hydrogen, a metal ion, a quaternary ammonium ion, lower alkyl, or comprised of a pharmaceutically active chemical compound or the precursor thereof; or X-G represents a carbonyl-activating group; J is lower alkyl, aryl, heteroaryl, omega-hydroxycarbonyl-(lower alkyl), omega-(lower alkoxy)carbonyl-(lower alkyl), omega-(X-G)-carbonyl-(lower alkyl) group, or compromised of a specific binding agent; and Ra, Rb, R1, R2, R3, R4 are as defined in the specification.
查看更多

同类化合物

胰岛素原(cattle),29-[N6-[[2-(甲磺酰)乙氧基]羰基]-L-赖氨酸]-59-[N6-[[2-(甲磺酰)乙氧基]羰基]-L-赖氨酸]-(9CI) 十氢-2,7-苯并二氧杂环癸烷-3,6-二酮 二环<3.3.0>-2-氧杂-5-(2-丙烯基)-1-辛烯 乙烯邻苯二甲酸酯 [(E,1R)-1-[(2R,4Z,7S,8R)-7-溴-8-乙基-3,6,7,8-四氢-2H-氧杂环辛三烯-2-基]己-3-烯-5-炔基]乙酸酯 [(2R,3S,4E,6R,7S)-6,7-二羟基-2-甲基-10-氧代-2,3,6,7,8,9-六氢氧杂环辛三烯-3-基] (E)-丁-2-烯酸酯 6,7-二氢-5aH-氧杂环丁烷并[3,2-d][1,3]苯并二氧戊环 5-氧杂-10-氮杂三环[5.3.1.03,8]十一碳-1(10),2,6,8-四烯 3-氧杂二环[3.3.1]壬-6-烯-9-酮 3,4,5,6-四氢-2,7-苯并二氧杂环癸烷e-1,8-二酮 17-苯基-18,19,20-三去甲-前列腺素F2-alpha1,15-内酯 10-(乙酰氧基)-4,5,6,7-四氢-2H-1-苯并氧杂环辛三烯-2,8(3H)-二酮 1-(2,3,4,5-四氢-1,6-苯并二噁辛英-8-基)丙烷-1-酮 1,2-环己烷二甲酸1-甲基-1,2-乙二基酯 (S)-5-烯丙基-2-氧杂双环[3.3.0]辛-8-烯 (R)-5-烯丙基-2-氧杂双环[3.3.0]辛-8-烯 (7Z)-2-(3-溴丙-1,2-二烯基)-5-(1-溴丙基)-3,3a,5,6,9,9a-六氢-2H-呋喃并[3,2-b]氧杂环辛三烯 (7E)-4,7-二羟基-10-甲基-3,4,5,6,9,10-六氢氧杂环辛三烯-2-酮 (6Z)-10-甲基-3,4,5,8,9,10-六氢-2H-氧杂环辛三烯-2-酮 (5Z,8S)-3-氯-2-[(E)-戊-2-烯-4-炔基]-8-[(E)-丙-1-烯基]-3,4,7,8-四氢-2H-氧杂环辛三烯 (4Z)-3,6-二氢-2,7-苯并二氧杂环癸烷e-1,8-二酮 (4S,5Z,7S,8S,10R)-4,7,8-三羟基-10-甲基-3,4,7,8,9,10-六氢氧杂环辛三烯-2-酮 (4R,5R,6Z,8S,10R)-4,5,8-三羟基-10-甲基-3,4,5,8,9,10-六氢氧杂环辛三烯-2-酮 (2R,5Z)-8a-[(R)-1-溴丙基]-3a-氯-3,4,7,8-四氢-2a-[(Z)-2-戊烯-4-炔基]-2H-氧杂环辛三烯 8-Chlor-1,6-benzodioxocin 2,2,6-Trifluoro-4-phenyl-3-trifluoromethyl-2H-pyran 2,3,4,5,6,7-Hexahydro-1-benzoxonin aspinolide C 4-deutero-4,5-dihydro-2H-benzo[b]oxocin-6(3H)-one 3-Carbethoxy-4-bromo-5,6-dihydro-2-pyron (E,8S,13S)-8,13-diisopropyl-5,8,9,12,13,16-hexahydro-6,15-dioxa-benzocyclotetradecene-7,14-dione (1S,7Z,10R,11S)-11-t-butyldimethylsolyloxy-4-oxabicyclo[8.3.0]tridec-7-en-3-one (Z)-2-Methyl-3a,4,5,6,7,9a-hexahydro-cycloocta[b]furan-3-carboxylic acid ethyl ester (5R,8S,9R,10S,E)-5,8,9-trihydroxy-10-methyl-3,4,5,8,9,10-hexahydro-2H-oxecin-2-one 19,21-Dimethyl-4,15-dioxa-bicyclo[16.2.2]docosa-1(21),18(22),19-triene-3,16-dione (1S,4aR,8aS)-1,4,4a,8a-Tetrahydro-naphthalen-1-ol 5-methyl-2-oxo-2H-cyclohepta[b]furan-3-carboxylic acid methyl ester trans,trans-2,3;10,11-Dibenzo-1,4,9,12-tetraoxa-cyclohexadecatetraen-(2,6,10,14) 1-C-(4-O-acetyl-2,3,6-trideoxy-β-L-erytro-hex-2-en-pyranosyl)-3-bromopentane 2,2,2-Trichloro-acetimidic acid (2S,3S,6R)-2-methoxy-6-methyl-3,6-dihydro-2H-pyran-3-yl ester 1-C-(4-O-acetyl-2,3,6-trideoxy-α-L-erytro-hex-2-en-pyranosyl)-5-bromopentane (3,4-dihydro-1H-2-benzopyran-7-yl)methanesulfonylchloride methyl 2,3-C-(2-butene-1,4-diyl)-2,3-dideoxy-α,β-D-talofuranoside 3-oxobicyclo<7.3.1>-trideca-1(12),9(10)-diene-(ZZ)-12-carboxylic acid (3aS,5S,6R,8aR)-6-Hydroxy-5-methyl-3,3a,4,5,6,8a-hexahydro-cyclohepta[b]furan-2-one (Z)-3-butyl-6,7,8,9-tetrahydrooxonin-2(5H)-one 3,6-dihydro-4-methyl-2H-1-benzoxocine 18,20-Dimethyl-4,14-dioxa-bicyclo[15.2.2]henicosa-1(20),17(21),18-triene-3,15-dione 3-butyl-5,6,7,8,9,10-hexahydro-2H-oxecin-2-one